JP7098643B2 - Ｈｉｖ／ａｉｄｓに対する強力な三環式ｐ２リガンド含有ｈｉｖプロテアーゼ阻害剤 - Google Patents

Ｈｉｖ／ａｉｄｓに対する強力な三環式ｐ２リガンド含有ｈｉｖプロテアーゼ阻害剤 Download PDF

Info

Publication number
JP7098643B2
JP7098643B2 JP2019545906A JP2019545906A JP7098643B2 JP 7098643 B2 JP7098643 B2 JP 7098643B2 JP 2019545906 A JP2019545906 A JP 2019545906A JP 2019545906 A JP2019545906 A JP 2019545906A JP 7098643 B2 JP7098643 B2 JP 7098643B2
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
chr
group
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019545906A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019534332A (ja
JP2019534332A5 (cg-RX-API-DMAC7.html
Inventor
アラン ケー． ゴーシュ
裕明 満屋
プラサンス レディ ニャラパトラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of JP2019534332A publication Critical patent/JP2019534332A/ja
Publication of JP2019534332A5 publication Critical patent/JP2019534332A5/ja
Application granted granted Critical
Publication of JP7098643B2 publication Critical patent/JP7098643B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2019545906A 2016-11-09 2017-11-09 Ｈｉｖ／ａｉｄｓに対する強力な三環式ｐ２リガンド含有ｈｉｖプロテアーゼ阻害剤 Active JP7098643B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662419850P 2016-11-09 2016-11-09
US62/419,850 2016-11-09
PCT/US2017/060840 WO2018089621A1 (en) 2016-11-09 2017-11-09 Tricyclic p2-ligand containing potent hiv-protease inhibitors against hiv/aids

Publications (3)

Publication Number Publication Date
JP2019534332A JP2019534332A (ja) 2019-11-28
JP2019534332A5 JP2019534332A5 (cg-RX-API-DMAC7.html) 2021-07-26
JP7098643B2 true JP7098643B2 (ja) 2022-07-11

Family

ID=62110761

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019545906A Active JP7098643B2 (ja) 2016-11-09 2017-11-09 Ｈｉｖ／ａｉｄｓに対する強力な三環式ｐ２リガンド含有ｈｉｖプロテアーゼ阻害剤

Country Status (5)

Country Link
US (2) US11028096B2 (cg-RX-API-DMAC7.html)
EP (1) EP3538090B1 (cg-RX-API-DMAC7.html)
JP (1) JP7098643B2 (cg-RX-API-DMAC7.html)
DK (1) DK3538090T3 (cg-RX-API-DMAC7.html)
WO (1) WO2018089621A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7098643B2 (ja) 2016-11-09 2022-07-11 パーデュー・リサーチ・ファウンデーション Ｈｉｖ／ａｉｄｓに対する強力な三環式ｐ２リガンド含有ｈｉｖプロテアーゼ阻害剤
CN109251208B (zh) * 2018-09-29 2020-03-20 山东农业大学 呋喃并吡喃衍生物在小麦田间防冻管理中的用途
CA3171361A1 (en) * 2020-03-18 2021-09-23 Arun K. Ghosh Tricyclic p2-ligand containing potent hiv-protease inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1634922A (zh) 2004-09-24 2005-07-06 中国科学院昆明植物研究所 抗艾滋病化合物,其制备方法和以该类化合物为活性成分的药物组合物及其应用
WO2015175994A1 (en) 2014-05-16 2015-11-19 Ghosh Arun K Hiv-1 protease inhibitors and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5946937B2 (ja) * 1975-12-30 1984-11-15 東レ株式会社 プロスタグランジンゴウセイチユウカンタイノセイゾウホウ
JPS5524139A (en) 1978-08-11 1980-02-21 Toray Ind Inc Optically active intermediate and its preparation
JPH05283436A (ja) 1992-03-31 1993-10-29 Hitachi Ltd パターン形成方法およびこの方法を用いたオフセットゲート電界効果トランジスタの製造方法
JPH0848678A (ja) 1994-06-02 1996-02-20 Banyu Pharmaceut Co Ltd 三環性ラクトン化合物の製造法
WO2012031237A1 (en) 2010-09-02 2012-03-08 Purdue Research Foundation Fused tricyclic ether carbamates and their use
WO2012092188A1 (en) 2010-12-27 2012-07-05 Ghosh Arun K Hydrogen bond forming p1 ligands and methods for treating hiv
JP7098643B2 (ja) 2016-11-09 2022-07-11 パーデュー・リサーチ・ファウンデーション Ｈｉｖ／ａｉｄｓに対する強力な三環式ｐ２リガンド含有ｈｉｖプロテアーゼ阻害剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1634922A (zh) 2004-09-24 2005-07-06 中国科学院昆明植物研究所 抗艾滋病化合物,其制备方法和以该类化合物为活性成分的药物组合物及其应用
WO2015175994A1 (en) 2014-05-16 2015-11-19 Ghosh Arun K Hiv-1 protease inhibitors and uses thereof

Also Published As

Publication number Publication date
DK3538090T3 (da) 2022-08-01
WO2018089621A1 (en) 2018-05-17
JP2019534332A (ja) 2019-11-28
EP3538090A1 (en) 2019-09-18
US20210261563A1 (en) 2021-08-26
US20190359626A1 (en) 2019-11-28
EP3538090B1 (en) 2022-06-22
EP3538090A4 (en) 2020-04-29
US11028096B2 (en) 2021-06-08
US11390630B2 (en) 2022-07-19

Similar Documents

Publication Publication Date Title
CN111225665B (zh) 大环免疫调节剂
CN111225896B (zh) 免疫调节剂化合物
JP5143916B2 (ja) 新規２環性複素環化合物
KR101991326B1 (ko) 오피오이드 수용체 리간드와 그 용도 및 제조방법
JP6622290B2 (ja) Ｈｉｖ−１プロテアーゼ阻害剤およびその用途
JP6107650B2 (ja) テトラヒドロカルボリン誘導体
JP7098643B2 (ja) Ｈｉｖ／ａｉｄｓに対する強力な三環式ｐ２リガンド含有ｈｉｖプロテアーゼ阻害剤
JP2022017516A (ja) Ｈｉｖ－１プロテアーゼ阻害剤およびその使用
CN114539229A (zh) 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
CN114516843A (zh) 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
WO2005102388A1 (ja) 新規なｂｌｔ２介在性疾患、ｂｌｔ２結合剤および化合物
US20070088021A1 (en) 4-haloisoquinoline derivative and drug containing the same
TW200407310A (en) Compounds
EP2021334B1 (en) Synthesis and uses of pyroglutamic acid derivatives
JP5667934B2 (ja) 新規２環性複素環化合物からなる医薬
JP7702424B2 (ja) 三環式ｐ２リガンドを含有する強力なｈｉｖプロテアーゼ阻害剤
CN112480100B (zh) 吡咯烷酮衍生物
KR101048748B1 (ko) 신규 갈바닉산 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 다약제내성 억제용 약학적 조성물
WO2006088080A1 (ja) シクロヘプタ［ｂ］ピリジン－３－カルボニルグアニジン誘導体およびそれを含有する医薬品
JP2025505419A (ja) チロシンキナーゼのイミダゾピリジン系阻害剤
US20030220385A1 (en) Treatment of disorder related to low cyclic GMP levels
JP2007169188A (ja) 新規安息香酸ベンジル誘導体及び医薬

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201105

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210518

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220422

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220519

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220601

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220629

R150 Certificate of patent or registration of utility model

Ref document number: 7098643

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250